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RESEARCH ARTICLE

Open Access

SR-A ligand and M-CSF dynamically regulate SR-A
expression and function in primary macrophages
via p38 MAPK activation
Dejan Nikolic1, Lindsay Calderon2, Liqin Du3 and Steven R Post1*

Abstract
Background: Inflammation is characterized by dynamic changes in the expression of cytokines, such as M-CSF,
and modifications of lipids and proteins that result in the formation of ligands for Class A Scavenger Receptors (SRA). These changes are associated with altered SR-A expression in macrophages; however, the intracellular signal
pathways involved and the extent to which SR-A ligands regulate SR-A expression are not well defined. To address
these questions, SR-A expression and function were examined in resident mouse peritoneal macrophages
incubated with M-CSF or the selective SR-A ligand acetylated-LDL (AcLDL).
Results: M-CSF increased SR-A expression and function, and required the specific activation of p38 MAPK, but not
ERK1/2 or JNK. Increased SR-A expression and function returned to basal levels 72 hours after removing M-CSF. We
next determined whether prolonged incubation of macrophages with SR-A ligand alters SR-A expression. In
contrast to most receptors, which are down-regulated by chronic exposure to ligand, SR-A expression was
reversibly increased by incubating macrophages with AcLDL. AcLDL activated p38 in wild-type macrophages but
not in SR-A-/- macrophages, and p38 activation was specifically required for AcLDL-induced SR-A expression.
Conclusions: These results demonstrate that in resident macrophages SR-A expression and function can be
dynamically regulated by changes in the macrophage microenvironment that are typical of inflammatory
processes. In particular, our results indicate a previously unrecognized role for ligand binding to SR-A in upregulating SR-A expression and activating p38 MAPK. In this way, SR-A may modulate inflammatory responses by
enhancing macrophage uptake of modified protein/lipid, bacteria, and cell debris; and by regulating the
production of inflammatory cytokines, growth factors, and proteolytic enzymes.

Background
SR-A is a multifunctional macrophage receptor that is
upregulated during monocyte differentiation into macrophages, and is further increased in pathological conditions such as diabetes [1-3]. SR-A is also highly
expressed by macrophages in atherosclerotic lesions and
Alzheimer’s plaques [4-6]. In contrast, decreased SR-A
expression is associated with increased susceptibility to
bacterial infection, progression of prostate cancer, and
enhanced cytokine production [7-9]. Such results suggest important and complex roles for SR-A in modulating immune function and inflammation.
* Correspondence: spost@uams.edu
1
Department of Pathology, University of Arkansas for Medical Sciences, Little
Rock, Arkansas, 72205 USA
Full list of author information is available at the end of the article

Macrophage differentiation and recruitment during
inflammation is mediated by changes in the local environment and the secretion of cytokines/chemokines such
as M-CSF. M-CSF, which is produced by many cell
types, is a cytokine that plays an essential role in monocyte-macrophage functions including membrane ruffling,
cell migration, and the production of inflammatory
mediators [reviewed in [10,11]]. Because of its role in
the development of monocyte/macrophage cells, M-CSF
is thought to play important roles in immune function
and inflammatory diseases [reviewed in [12]]. For example, M-CSF is thought to promote atherosclerosis by
increasing macrophage viability/differentiation, low-density lipoprotein (LDL) receptor-mediated lipoprotein
uptake, and the expression of macrophage SR-A [12-14].
SR-A promotes foam cell formation by binding and
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internalizing modified lipoproteins [e.g., acetylated LDL
(AcLDL), oxidized LDL (oxLDL)], but not native lipoproteins [15]. SR-A has also been associated with additional macrophage functions including cell adhesion to
modified extracellular matrix, phagocytosis/clearance of
apoptotic cells, and the modulation of macrophage activation and cytokine production [16-20]. Thus, increased
SR-A expression may play an important part in the
effects of M-CSF on immune function and inflammation. Taken further, the ability to inhibit M-CSF-induced
SR-A expression may have important therapeutic implications. However, the cellular pathways that couple MCSF binding to increased SR-A expression are not
known.
In addition to increased secretion of M-CSF, local
inflammation results in the modification of proteins,
alterations in the extracellular matrix (ECM), and tissue
damage. Such modifications result in the formation and
accumulation of SR-A ligands. Many receptors including
receptor-tyrosine kinases (e.g., insulin receptors), G protein-coupled receptors (e.g., b-adrenergic receptors), and
nutrient receptors (e.g., LDL receptors) are down-regulated by prolonged exposure to ligand. This negative
feedback is mediated by activation of intracellular signaling pathways that regulate receptor expression.
Although it might be of particular importance in diverse
inflammatory conditions, the effect of modulating the
concentration of SR-A ligand in tissue on SR-A expression in resident macrophages is not known.
SR-A gene expression is under the control of a proximal promoter in combination with an upstream enhancer element [2,21,22]. Binding of the transcription factor
AP-1 to this upstream enhancer element has been
shown to be sufficient to direct specific macrophage SRA expression [1,22]. Activation of AP-1 in inflammatory
cells is primarily regulated by the mitogen activated protein kinases (MAPK), in particular via c-Jun phosphorylation by JNK and ATF2 phosphorylation by p38 MAPK
[23]. Roles for both of these MAPKs in regulating SR-A
expression in elicited macrophages has been suggested
[24,25].
It has been suggested that different agents used to elicit resident peritoneal macrophages can alter macrophage populations, their regulation by intracellular
signals, and macrophage responses e.g., superoxide production, chemokine generation, and Ab-dependent cellmediated cytolysis [26,27]. In this study, we used isolated resident peritoneal macrophages to examine the
intracellular signaling pathways involved in regulating
SR-A expression and function. We also examined
whether chronic exposure to SR-A ligand alters SR-A
expression in macrophages. Our results demonstrate
that cytokine and SR-A ligand reversibly enhance SR-A
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expression and function via activation of p38 MAPK
and the subsequent induction of SR-A transcription.

Methods
Chemicals

Dulbecco’s modified Eagle’s medium (DMEM) supplemented with L-glutamine, DMEM with 25 mM HEPES,
and heat-inactivated fetal bovine serum (FBS) were purchased from GibcoBRL (Grand Island, NY). Penicillin
and streptomycin, fucoidan, and actinomycin D were
purchased from Sigma (St Louis, MO). Recombinant
murine M-CSF and goat anti-mouse SR-A antibody
were purchased from R&D Systems (Minneapolis, MN).
Rabbit anti-phospho-p44/42 (ERK1/2), anti-phosphop38, anti-phospho-SAPK/JNK, and anti-p38 MAPK antibodies were purchased from Cell Signaling Technology,
Inc. (Beverly, MA). Anti-p44/42 (ERK1/2) and antiJNK1 antibodies were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). The specific MAPK
inhibitors SB203580 (p38), SP600125 (JNK1/2), and
PD98059 (MEK) were purchased from EMD Biosciences, Inc (La Jolla, CA). Alexa488-Acetylated LDL was
purchased from Molecular Probes, Inc (Eugene, OR)
and Alexa647-conjugated 2F8 mAb from Serotec.
Cell culture and treatment

Resident (non-elicited) mouse peritoneal macrophages
(MPMs) were harvested by peritoneal lavage with icecold sterile saline from male NIH Swiss mice (Harlan;
Indianapolis, IN), and from C57Bl/6 and SR-A-/- mice
on a C57Bl/6 background (Figures 1C and 4B; Jackson
Laboratory, Bar Harbor, ME). Animal care and use for
all procedures were done according to protocols
reviewed and approved by the Institutional Animal Care
and Use Committee at University of Arkansas for Medical Sciences and the University of Kentucky. Isolated
macrophages were cultured as previously described [28].
Briefly, peritoneal exudates were incubated overnight at
37°C and non-adherent cells removed by gently washing
with PBS. Adherent macrophages were maintained in
DMEM containing antibiotics and FBS (10%) for 48 hrs
prior to use in experiments. MPMs were then treated
with agonists in the presence or absence of specific inhibitors as described in figure legends. Following treatment, MPMs were washed with ice-cold PBS and cell
lysates prepared by incubating cells in MBST/OG buffer
(25 mM MES; 150 mM NaCl; 60 mM octylglucopyranoside; 1% Triton X-100; pH 6.4) containing protease and
phosphatase inhibitors (Sigma, St. Louis, MO) for 45 min
on ice. Cell lysates were centrifuged at 13,000 rpm for 15
min and the pellets were discarded. Protein concentration of supernatant was determined using the BioRad DC
assay using BSA as a standard (Hercules, CA).
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Figure 1 M-CSF induces SR-A expression and AcLDL association. (A) Cultured resident MPMs were incubated with the indicated
concentrations of M-CSF for 24 hrs. Subsequently, SR-A and GAPDH proteins were detected in lysates prepared from treated cells by
immunoblotting with specific antibodies. A representative immunoblot from a single experiment and the results (mean ± SEM) from at least
three separate experiments are shown. (B) Cultured resident MPMs were pretreated with actinomycin D (5 μM) for 30 min, and then incubated
with or without M-CSF (25 ng/ml) for the indicated times prior to assessing SR-A expression. A representative immunoblot from a single
experiment and the results (mean ± SEM) from at least three separate experiments are shown. (C) Alexa488-AcLDL association with macrophages
isolated from C57Bl/6 or NIH-Swiss mice was quantified by flow cytometry as described in Material and Methods. Non-specific association was
determined in the presence of fucoidan (Fuc, 75 μg/ml), a blocking SR-A antibody (2F8, 10 μg/ml), or by using SR-A-/- macrophages. Shown is
the mean ± SEM of three separate experiments. (D) SR-A-specific Alexa488-AcLDL association with macrophages incubated with M-CSF (25 μg/
ml) for the indicated times was quantified by flow cytometry as described in Material and Methods. The results of a representative experiment
and the mean ± SEM of at least three separate experiments are shown. (E) Relative changes in SR-A expression and function were plotted and
the best fit line determined using a Deming linear regression model in GraphPad Prism.

Nikolic et al. BMC Immunology 2011, 12:37
http://www.biomedcentral.com/1471-2172/12/37

Western blot analysis

Equal amounts of cell lysate protein were resolved by
12% SDS-PAGE and transferred to polyvinylidene
difluoride (PVDF) membrane (Millipore, Billerica, MA).
Proteins were detected by immunoblotting with specific
primary antibodies followed by incubation with speciesspecific HRP-conjugated secondary antibodies. Bands
were visualized by chemiluminescence, images captured
with a Kodak Image Station 4000 MM Pro, and band
intensities quantified using Kodak 1D image analysis
software.
Flow Cytometry

To assess SR-A-mediated lipoprotein uptake and surface
accessible SR-A, cultured MPMs were preincubated for
2 hrs in serum-free DMEM and then incubated for 2
hrs at 37°C with Alexa488-AcLDL(2.5 μg/ml). Nonspecific association of Alexa488-AcLDL with cells was defined
in the presence of the SR-A ligand fucoidan (75 μg/ml)
for 5 minutes prior to addition of lipoprotein. Nonspecific values were subtracted from total values to calculate
SR-A-specific cell association. To quantify surface SR-A,
MPMs were washed and incubated in DMEM/1% FBS
containing Alexa647-conjugated 2F8 mAb for 30 min at
25°C. Cells were then washed and suspended in PBS,
and Alexa488-AcLDL and Alexa647-conjugated antibody
association quantified by flow cytometry.

Results and Discussion
M-CSF induces SR-A expression and AcLDL association

Macrophage differentiation and recruitment into
inflammatory sites are associated with increased SR-A
expression. SR-A expression is regulated by both transcriptional and post-transcriptional processing
[1,3,14,25,28-30]. M-CSF is involved in both monocyte/
macrophage differentiation and recruitment during
inflammation, and has previously been shown to
enhance SR-A expression in elicited macrophages via
increased transcription [14]. However, the intracellular
signals that couple M-CSF to enhanced SR-A expression
have not been defined.
To examine the signaling pathways that regulate SR-A
expression, the effect of M-CSF on SR-A expression was
examined in non-elicited, resident MPMs. Non-elicited,
resident MPMs were used because of the potential for
eliciting agents to alter macrophage phenotype and regulation by intracellular signals. Culturing isolated MPMs
with M-CSF resulted in the concentration-(Figure 1A)
and time-(Figure 1B) dependent induction of SR-A protein expression. SR-A expression was increased by incubating macrophages with physiologically relevant (0.5-75
ng/ml) concentrations [31-33] of M-CSF (EC50 ≈5 ng/
ml), and was maximally induced following a 24 hr incubation with M-CSF (Figure 1B). No further increase in
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expression was observed with longer times of incubation
with M-CSF (data not shown). Treating MPMs with
actinomycin D (5 μM), an inhibitor of gene transcription, prior to incubation with M-CSF abolished M-CSFmediated upregulation of SR-A expression indicating
that M-CSF-stimulated SR-A expression in resident
macrophages results from increased SR-A transcription.
To confirm that increased SR-A expression is correlated
with enhanced SR-A function, we examined the ability
of M-CSF to stimulate fluorescently-labeled AcLDL
(Alexa 488 -AcLDL) association with MPMs. Results
shown in Figure 1C show that a blocking SR-A monoclonal antibody (2F8) and an excess of SR-A competitor
(fucoidan) reduced AcLDL association with macrophages isolated from C57Bl/6 or NIH-Swiss mice to a
level similar to that obtained using macrophages isolated
from SR-A-/- in a C57Bl/6 background. These results
demonstrate the specificity of this asssay for assessing
SR-A function. M-CSF treatment induced a time-dependent increase in AcLDL association with MPMs that
was maximal (2.4-fold) at 24 hrs (Figure 1D), with no
further increase at longer incubation times (data not
shown). M-CSF stimulation of SR-A function was linearly correlated (Pearson r = 0.97; p = 0.007) with the
effect of M-CSF on SR-A expression (Figure 1E) indicating that in resident MPMs SR-A function is limited, at
least in part, by the level of receptor expression. These
results suggest that by increasing SR-A expression MCSF, produced for example by endothelial cells or lymphocytes in an atherosclerotic plaque or other inflammatory sites, can increase the uptake of modified
lipoprotein and other scavenger receptor ligands.
M-CSF-stimulates SR-A expression by upregulating SR-A
mRNA and protein synthesis which requires p38 MAPK
activation

Many effects of M-CSF including macrophage migration, differentiation, survival, and cytokine production
are mediated, in part, via activation of MAPKs, a family
of kinases that include ERK1/2, JNK, and p38 [34-36].
Activation of MAPKs, in particular JNK and p38
MAPK, regulates the activity of several transcription factors including AP-1 [23]. The binding of AP-1 to an
upstream enhancer element is sufficient to direct specific macrophage SR-A expression in inflammatory cells
[1,21,22]. Therefore, we examined M-CSF-dependent
MAPK activation and whether MAPK activation was
required for M-CSF-induced SR-A expression. For this,
resident MPMs were treated with M-CSF and the activation of ERK, p38, and JNK assessed by immunoblotting with phospho-specific MAPK antibodies. As shown
in Figure 2A, M-CSF induced the phosphorylation of
both p38 and ERK1/2. In contrast, JNK phosphorylation
was not detectable in either the presence or absence of
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(A) MPM were incubated with or without M-CSF (25 ng/ml) for 10 min at 37°C. Cells were then lysed with MBST/OG buffer and phosphorylation
of MAPK quantified by immunobloting. The results from a single experiment are shown and are representative of at least four separate
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untreated control value (ANOVA with Dunnett’s multiple comparison). (C) MPM were treated with specific inhibitors of p38 [SB203580 (10 μM)],
JNK [SP600125 (20 μM)] or ERK1/2 [PD98059 (10 μM)] for 20 minutes at 37°C, and then incubated with M-CSF (25 ng/ml) for 24 hrs. SR-A-specific
macrophage association was quantified by flow cytometry as described in Materials and Methods. Data represent the mean ± SEM from at least
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M-CSF (data not shown). To determine if activation of
MAPK was specifically required for M-CSF-induced SRA expression and function, the ability of M-CSF to stimulate SR-A expression and AcLDL association was
assessed in MPMs pretreated with specific inhibitors of
p38 MAPK (SB203580), JNK (SP600125), and MEK1
(PD98059), which inhibits ERK1/2 activation. Inhibiting
JNK or ERK1/2 activation had no effect on either
M-CSF-induced SR-A expression (Figure 2B) or M-CSFinduced uptake of modified lipoprotein (Figure 2C). In
contrast, pretreating macrophages with SB203580 inhibited both M-CSF-induced SR-A expression and modified
lipoprotein uptake (Figure 2C). Together, these data
define a specific requirement for activation of p38
MAPK, but not ERK1/2 and JNK, in M-CSF-induced
SR-A expression and function.
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the pretreated levels 72 hr after M-CSF removal (t 1/2 ≈
24 hr). To determine if SR-A expression was still
responsive to M-CSF, previously treated MPMs were restimulated with M-CSF for another 30 hrs. Similar to
naïve MPMs, SR-A expression and function were
increased by the restimulation with M-CSF. As summarized in Figure 3D, M-CSF-induced proportional changes
in SR-A expression and function in both naïve and previously treated MPMs. Together, these data demonstrate
that in resident macrophages SR-A expression and function is dynamically regulated by M-CSF.
AcLDL stimulates SR-A expression in reversible manner
via activation of p38 MAPK

In addition to cytokines, inflammatory settings are characterized by accumulation of SR-A ligands including
oxidized lipoproteins (e.g., modified LDL), necrotic cell
debris, and modified ECM. Because many receptors are
down-regulated by chronic exposure to ligand, we tested
whether SR-A expression was decreased by ligand. In
contrast to our hypothesis, incubating macrophages with
an SR-A selective ligand (AcLDL; 50 μg/ml) for 24 hr
increased SR-A protein expression (Figure 4A). As
demonstrated for M-CSF, enhanced SR-A expression
returned to the pretreated levels 72 hr after AcLDL was
removed, and pre-treating MPMs with a specific p38
MAPK inhibitor (SB203580) blocked AcLDL-induced
SR-A expression. In contrast, inhibitors of ERK1/2 and
JNK did not affect the ability of AcLDL to enhance SRA expression. To confirm that incubating resident
MPMs with AcLDL induced SR-A-dependent MAPK
activation, the ability of AcLDL to activate MAPK in
wild-type and SR-A deficient resident MPMs was examined. As shown in Figure 4B, treating macrophages with
AcLDL (50 μg/ml, 10 min) induced phosphorylation of
p38 MAPK and ERK1/2 in wild-type but not in SR-A
deficient macrophages. In contrast, p38 MAPK and
ERK1/2 phosphorylation were similarly increased in
both wild type and SR-A deficient MPMs treated with
M-CSF. JNK phosphorylation was not detected in any
treatment group (data not shown). Together, these data
indicate that ligand binding to SR-A is positively
coupled to SR-A expression via specifically activating
p38 MAPK.
Regulating SR-A expression in vivo may be relevant to
many inflammatory disorders. For example, M-CSF
plays important roles in inflammation and immunity.
M-CSF increases anti-tumor and anti-infective functions
of macrophages, whereas M-CSF deficiency decreases
atherosclerosis and impairs osteoclast development
[11,37]. The extent to which these effects depend on
altered SR-A expression remains to be defined. However, the possibility that regulating SR-A expression

Page 8 of 10

modulates inflammatory responses is suggested by the
many studies showing that decreased SR-A expression is
associated with reduced atherosclerosis, increased susceptibility to infection, disease progression in prostate
cancer, and dysregulation of bone development
[8,9,38-40]. Like SR-A, activation of p38 MAPK is
important for many inflammatory processes including
the production of TNFa, IL-1b, and other cytokines
[41,42]. In addition, inhibiting p38 MAPK has shown
potential benefit in the treatment of inflammatory disease [43,44]. Our findings suggest that the effects of MCSF and p38 MAPK on immune and inflammatory processes may be mediated, in part, by modulating SR-A
expression.

Conclusions
Our results indicate that resident tissue macrophages
adapt to changes in their local environment by modulating SR-A expression and function. Such modulation
may involve the local secretion of M-CSF, which
increases SR-A expression via activating p38 MAPK.
Unlike many receptor systems which are down-regulated
by ligand, ligand binding to SR-A up-regulates SR-A
expression by activating p38 MAPK. Increased SR-A
expression might modulate inflammation by enhancing
macrophage uptake and clearance of modified protein/
lipid, bacteria, and cell debris. In addition, SR-Amediated p38 MAPK activation may regulate the production of inflammatory cytokines, growth factors, and
proteolytic enzymes, and therefore modulate the progression of many inflammatory disorders [18-20]. This
may be of particular importance in settings where SR-A
ligands accumulate such as atherosclerosis, diabetes, and
Alzheimer’s disease.
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